Claims
- 1. A compound of Formula (I) represented by the structure:
- 2. The compound according to claim 1 wherein Z is —NH—, n is an integer of 0 and X is aryl optionally substituted or a pharmaceutically acceptable salt thereof.
- 3. The compound according to claim 2 wherein X is phenyl optionally substituted or a pharmaceutically acceptable salt thereof.
- 4. The compound according to claim 1 wherein X is substituted or unsubstituted bicyclic aryl or bicyclic heteroaryl ring system, or a pharmaceutically acceptable salt thereof.
- 5. The compound according to claim 1 wherein Z is —NH—, n is an integer of 0, X is aryl optionally substituted and G1 and G4 are H or a pharmaceutically acceptable salt thereof.
- 6. The compound according to claim 1 wherein X is the radical:
- 7. The compound according to claim 4 wherein the bicyclic aryl or bicyclic heteroaryl ring system is selected from the group consisting of naphthaline, 1,2,3,4-tetrahydronaphthaline, indane, 1-oxo-indane, 1,2,3,4-tetrahydroquinoline, naphthyridine, benzofuran, 3-oxo-1,3-dihydroisobenzofuran, benzothiaphene, 1,1-dioxobenzothiaphene, indole, 2,3-dihydroindole, 1,3-dioxo-2,3-dihydro-1H-isoindole, benzotriazole, 1H-indazole, indoline, benzopyrazole, 1,3-benzodioxole, benzoxazole, purine, phthalimide, coumarin, chromone, quinoline, terahydroquinoline, isoquinoline, benzimidazole, quinazoline, pyrido[2,3-b]pyridine, pyrido[3,4-b]pyrazine, pyrido[3,2-c]pyridazine, pyrido[3,4-b]pyridine, 1H-pyrazole[3,4-d]pyrimidine, 1,4-Benzodioxane, pteridine, 2(1H)-quinolone, 1(2H)-isoquinolone, 2-oxo-2,3-dihydrobenzthiazole, 1,2-methylenedioxybenzene, 2-oxindole, 1,4-benzisoxazine, benzothiazole, quinoxaline, quinoline-N-oxide, isoquinoline-N-oxide, quinoxaline-N-oxide, quinazoline-N-oxide, benzazine, phthalazine, 1,4-dioxo-1,2,3,4-tetrahydrophthalazine, 2-oxo-1,2-dihydroquinoline, 2,4-dioxo-1,4-dihydro-2H-benzo[d][1,3]oxazine, 2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine, and cinnoline or a pharmaceutically acceptable salt thereof.
- 8. The compound according to claim 6 wherein L is 5 or 6-membered heteroaryl ring or a pharmaceutically acceptable salt thereof.
- 9. The compound according to claim 8 wherein the heteroaryl ring is selected from the group consisting of pyridine, pyrimidine, imidazole, thiazole, thiazolidine, pyrrole, furan, thiophene, oxazole, and 1,2,4-triazole or a pharmaceutically acceptable salt thereof.
- 10. The compound according to claim 6 wherein L is an optionally substituted aryl ring or a pharmaceutically acceptable salt thereof.
- 11. The compound according to claim 1, which is:
N-(4-{3-chloro-4-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]anilino}-3-cyano-7-methoxy-6-quinolinyl)-3,4-bis(dimethylamino)-2-butanamide or a pharmaceutically acceptable salt thereof.
- 12. The compound according to claim 1, which is:
N-[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-3,4-bis-(3-hydroxy-pyrrolidin-1-yl)-butyramide or a pharmaceutically acceptable salt thereof.
- 13. The compound according to claim 1, which is:
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-3-(dimethylamino)butanamide or a pharmaceutically acceptable salt thereof.
- 14. The compound according to claim 1, which is:
N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-3,6-bis(dimethylamino)hexanamide or a pharmaceutically acceptable salt thereof.
- 15. The compound according to claim 1, which is:
N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-3,4-di(1-pyrrolidinyl)butanamide or a pharmaceutically acceptable salt thereof.
- 16. The compound according to claim 1, which is:
(2R)-2-amino-5-({2-[(carboxymethyl)amino]-1-[({3-{[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]amino}-1-[(dimethylamino)methyl]-3-oxopropyl}sulfanyl)methyl]-2-oxoethyl}amino)-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.
- 17. The compound according to claim 1, which is:
N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-3,4-bis(dimethylamino)butanamide or a pharmaceutically acceptable salt thereof.
- 18. A method of treating, inhibiting the growth of, or eradicating neoplasms in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) represented by the structure
- 19. The method according to claim 18 wherein the neoplasm is selected from the group consisting of breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, and lung.
- 20. A method of treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) represented by the structure:
- 21. A method of treating, inhibiting, or eradicating colonic polyps in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) represented by the structure:
- 22. A pharmaceutical composition which comprises a compound of Formula (I) represented by the structure
- 23. The compound according to claim 1, which is N-{4-[4-(Benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-3,4-bis(dimethylamino)butanamide or a pharmceutically acceptable salt thereof.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] “This application claims priority from copending provisional application Serial No. 60/333,568 filed on Nov. 27, 2001 the entire disclosure of which is hereby incorporated by reference.”
Provisional Applications (1)
|
Number |
Date |
Country |
|
60333568 |
Nov 2001 |
US |